A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DR 01 (Primary)
Indications Large granular lymphocytic leukaemia; Lymphoma
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Dren Bio

Most Recent Events

05 Feb 2025 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.
05 Feb 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2026.
21 Nov 2024 event According to a City of Hope media release, data from this will be presented in oral poster presentations at ASH annual meeting from Dec. 7 to 10 in San Diego.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight